Navigation Links
GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
Date:8/11/2008

ATLANTA, Aug. 11 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, biopharmaceutical firm (the Company), developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its financial results and provided an operational update for the six months ended June 30, 2008.

Financial Results for the Three Months and Six Months Ended June 30, 2008

The Company recorded a net loss of $1,284,352 for the three months ended June 30, 2008, compared to $1,333,126 for the same period in 2007. For the six months ended June 30, 2008, the Company's net loss was $1,966,862 as compared to $1,920,407 in 2007. Net losses for 2008 were partially offset by grant revenues of $376,078 and $976,069 for the three month and six month periods, respectively, related to the Company's grant from the National Institutes of Health in support of its HIV/AIDS vaccine development activities. As of June 30, 2008, the Company reported cash balances totaling $3,133,839.

Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

Management Commentary

Robert McNally, GeoVax's President & CEO, commented, "We are pleased with our six month financial results, including our operational expenses and cash position. Our operational expenses are minimal for a company of our size and stage of clinical trial development. We are particularly pleased with the financing strategy provided by the $10 million common stock purchase agreement with Fusion Capital Fund II, LLC. Funding from the Fusion facility will be utilized for the large Phase 2 preventative AIDS vaccine clinical trial planned to begin this fall and initiation of the therapeutic trial in HIV infected and drug-treated humans."

Dr. McN
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. GeoVax Further Strengthens Management Team
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
4. Genaera Corporation Announces Second Quarter Financial Results
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
7. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
8. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 Sales Horizons, ... launch of blended sales training programs for companies engaged ... training programs used by thousands of salespeople over 25 ... sales training program can be customized to address the ... The blended sales training program consists of ...
(Date:7/30/2014)... 30, 2014 With the accelerated ... personal health expenditure as well as the improved ... China diagnostic reagent industry has been developing quickly, ... In 2013, Chinese in vitro diagnostics market size ... from in vitro diagnostic reagents. , Read ...
(Date:7/30/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... Industrial Applications , the global market for industrial enzymes ... 2018, registering a five-year compound annual growth rate (CAGR) ... in the detergent enzyme segment with a CAGR of ... influenced almost every sector of industrial activity, ranging from ...
(Date:7/30/2014)... Yuma Regional Cancer Center Officially Opens ... comprehensive cancer care to Yuma, Arizona. , The ... has officially opened. A Mayo Clinic Care Network ... as open, semi-private and private infusion rooms, oncology ... Center, hematology, rehabilitation center, a pain management program ...
Breaking Biology Technology:Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2
... a small cabinet the size of a dorm refrigerator in one ... glass bottles under the cool light of red, blue and green ... soup of champions. The soup is colored by a strain ... gas produced by their nearest competitorsin part because of their unique ...
... Reportlinker.com announces that a new market research report ... Applications and Global Markets http://www.reportlinker.com/p0341184/Nanobiotechnology-Applications-and-Global-Markets.html ... products is $19.3 billion in 2010 and is growing ... to reach a forecast market size of $29.7 billion ...
... COLUMBIA, Md., Dec. 14, 2010 Cylex Incorporated® ... Medicaid Services (CMS) nearly tripled the reimbursement ... FDA-cleared for the detection of cell-mediated immune response ...  This significant increase was granted in a time ...
Cached Biology Technology:Champion hydrogen-producing microbe 2Champion hydrogen-producing microbe 3Champion hydrogen-producing microbe 4Reportlinker Adds Nanobiotechnology: Applications and Global Markets 2Reportlinker Adds Nanobiotechnology: Applications and Global Markets 3Reportlinker Adds Nanobiotechnology: Applications and Global Markets 4Reportlinker Adds Nanobiotechnology: Applications and Global Markets 5Reportlinker Adds Nanobiotechnology: Applications and Global Markets 6Reportlinker Adds Nanobiotechnology: Applications and Global Markets 7Reportlinker Adds Nanobiotechnology: Applications and Global Markets 8Reportlinker Adds Nanobiotechnology: Applications and Global Markets 9Reportlinker Adds Nanobiotechnology: Applications and Global Markets 10Reportlinker Adds Nanobiotechnology: Applications and Global Markets 11Reportlinker Adds Nanobiotechnology: Applications and Global Markets 12Reimbursement Rate Nearly Tripled for Cylex's ImmuKnow® Assay 2
(Date:7/30/2014)... from Bjorn Brembs, professor of neurogenetics at the Institute ... figure allowing readers and reviewers to run the underlying ... important leap forward for scientific publishing, by demonstrating a ... scholarly output. , Figure 3 in fact doesn,t really ... to F1000Research , and the figure is generated ...
(Date:7/30/2014)... cord injury (SCI), traumatic brain injury (TBI) and peripheral ... been learned over the past 30 years regarding both ... axon growth, but this large body of information has ... and his team from University of Miami in USA ... a consensus is emerging that one contributing factor is ...
(Date:7/30/2014)... today in the journal Scientific Reports , published ... Auroop Ganguly found that while global temperature is indeed ... For instance, while each year,s average hottest and coldest ... to fall within a wider range of potential high ... This means that even as overall temperatures rise, we ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2Big data confirms climate extremes are here to stay 2
... March 4, 2009 The incidence of pneumothorax (PTX), or ... trauma has been reported to range from 13 50 ... In people, PTX is reported to be the most ... Thoracic ultrasound has been infrequently used as a non-invasive, point-of-care ...
... not lower, costs and very large reductions in greenhouse ... the key take-home messages from a series of expert ... Future (RBAEF)" in a special issue of Biofuels, ... that the collection, which includes a comparative analysis of ...
... March 3, 2009 "Undesirable" evolution in fish ... dwindle -- can actually be reversed in a few ... fishing, according to groundbreaking new research published today by ... Royal Society B . Intensive harvesting of the ...
Cached Biology News:Novel veterinary procedure detecting life-threatening injuries touted 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 3'Undesirable' evolution can be reversed in fish, Stony Brook University scientists show 2'Undesirable' evolution can be reversed in fish, Stony Brook University scientists show 3
Mouse monoclonal [TU-20] to beta III Tubulin (FITC) ( Abpromise for all tested applications). entrezGeneID: 10381 SwissProtID: Q13509...
Sheep polyclonal to Methaqualone ( Abpromise for all tested applications). Antigen: Methaqualone(5') conjugated to BSA...
Mouse monoclonal [CP23] to Ricin communis ( Abpromise for all tested applications)....
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: